[
  {
    "sentence": "This comprehensive review provides a synthesis of the latest current knowledge, focusing on recent breakthroughs and emerging trends in the pathogenesis, progression, diagnostics, treatment, and follow-up management of breast cancer (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Specific genes related to the progression of breast cancer\n\n\nGenes\nVariation\nCellular function and mechanisms of progression\nReference\n\n\n\nNF1\nMutation\nInhibiting RAS/Raf pathway and promote ER phosphorylation\n28\n\n\nESR1\nMutation, copy number variation, gene fusion\nInducing constitutive ER activity, leading to induction of ER target gene transcription that is resistant to endocrine blockade\n29–34\n\n\nALDH2\nCopy number gain\nCopy number gain of ALDH2 are associated with the expansion of subclones with high metastatic potential and shorter patient survival\n35,36\n\n\nGATA3\nMutation\nNegatively regulating the expression of several genes that promote breast cancer metastasis\n37\n\n\nKMT2C\nMutation\nDriving metastasis of TNBC via KDM6A-matrix metalloproteinase 3 axis\n38,39\n\n\nPTEN\nGene loss\nUp regulating CCL2 expression increase the number of CCR2-dependent macrophages, and promote PI3K/ Akt signaling pathway\n40\n\n\nFOXM1\nUpregulate gene expression\nPromoting the transcription of G2 and M phase genes in tumor cells through the PI3K/ Akt/mTOR pathway\n41\n\n\nYTHDF3\nUpregulate gene expression\nBinding to the m6A methylation site of YTHDF3\n42\n\n\nP53\nDownregulate gene expression\nPromoting the secretion of IL-1β by macrophages and the Wnt/β-catenin pathway\n43\n\n\nPI3KCA\nMutation\nActivating the PI3K enzyme and signaling pathway\n44,45\n\n\nRB1\nMutation\nAffecting the CDK-Rb-E2F signaling pathway\n44,46\n\n\n\nOpen in a new tab\nER estrogen receptor, TNBC triple-negative breast cancer, ALDH2 aldehyde dehydrogenase 2 family member 2, KDM6A lysine specific demethylase 6A, YTHDF3 YTH domain family 3, CCL2 C-C Motif Chemokine Ligand 2, PI3K phosphoinositide 3-kinase, RB Retinoblastoma retinoblastoma gene 1, CDK cyclin-dependent kinase, E2F E2 factorThe leading risk factors involve a combination of genetic predisposition, hormonal factors, reproductive history, and lifestyle choices (Fig. 2).5\nFig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is worth noting that retesting of the hormone and HER2 receptors should be considered in certain situations to optimize adjuvant systemic therapy.123Molecular subtypes of breast cancer\nThe past few decades have witnessed the promotion and popularization of the concept of classification-based treatment (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Lehmann et al. divided TNBC into six subtypes from the molecular classification: basal-like 1/2, immune modulative, mesenchymal, mesenchymal stem cell-like, and luminal androgen receptor subtypes,128and subsequently Burstein et al. refined the six TNBC subtypes into four subgroups.129 Based on the cohort from Fudan University Shanghai Cancer Center, molecular classifications of TNBC and HR+/HER2− breast cancer were further developed.130–132\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Belows are highlighted some key factors contributing to the progression of breast cancer (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Based on these principles, numerous innovative explorations are emerging in both the surgical and radiotherapy fields (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The paradigm of systemic therapy has shifted from traditional methods to subtype-specific and personalized approaches (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This comprehensive review provides a synthesis of the latest current knowledge, focusing on recent breakthroughs and emerging trends in the pathogenesis, progression, diagnostics, treatment, and follow-up management of breast cancer (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Specific genes related to the progression of breast cancer\n\n\nGenes\nVariation\nCellular function and mechanisms of progression\nReference\n\n\n\nNF1\nMutation\nInhibiting RAS/Raf pathway and promote ER phosphorylation\n28\n\n\nESR1\nMutation, copy number variation, gene fusion\nInducing constitutive ER activity, leading to induction of ER target gene transcription that is resistant to endocrine blockade\n29–34\n\n\nALDH2\nCopy number gain\nCopy number gain of ALDH2 are associated with the expansion of subclones with high metastatic potential and shorter patient survival\n35,36\n\n\nGATA3\nMutation\nNegatively regulating the expression of several genes that promote breast cancer metastasis\n37\n\n\nKMT2C\nMutation\nDriving metastasis of TNBC via KDM6A-matrix metalloproteinase 3 axis\n38,39\n\n\nPTEN\nGene loss\nUp regulating CCL2 expression increase the number of CCR2-dependent macrophages, and promote PI3K/ Akt signaling pathway\n40\n\n\nFOXM1\nUpregulate gene expression\nPromoting the transcription of G2 and M phase genes in tumor cells through the PI3K/ Akt/mTOR pathway\n41\n\n\nYTHDF3\nUpregulate gene expression\nBinding to the m6A methylation site of YTHDF3\n42\n\n\nP53\nDownregulate gene expression\nPromoting the secretion of IL-1β by macrophages and the Wnt/β-catenin pathway\n43\n\n\nPI3KCA\nMutation\nActivating the PI3K enzyme and signaling pathway\n44,45\n\n\nRB1\nMutation\nAffecting the CDK-Rb-E2F signaling pathway\n44,46\n\n\n\nOpen in a new tab\nER estrogen receptor, TNBC triple-negative breast cancer, ALDH2 aldehyde dehydrogenase 2 family member 2, KDM6A lysine specific demethylase 6A, YTHDF3 YTH domain family 3, CCL2 C-C Motif Chemokine Ligand 2, PI3K phosphoinositide 3-kinase, RB Retinoblastoma retinoblastoma gene 1, CDK cyclin-dependent kinase, E2F E2 factorThe leading risk factors involve a combination of genetic predisposition, hormonal factors, reproductive history, and lifestyle choices (Fig. 2).5\nFig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is worth noting that retesting of the hormone and HER2 receptors should be considered in certain situations to optimize adjuvant systemic therapy.123Molecular subtypes of breast cancer\nThe past few decades have witnessed the promotion and popularization of the concept of classification-based treatment (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Lehmann et al. divided TNBC into six subtypes from the molecular classification: basal-like 1/2, immune modulative, mesenchymal, mesenchymal stem cell-like, and luminal androgen receptor subtypes,128and subsequently Burstein et al. refined the six TNBC subtypes into four subgroups.129 Based on the cohort from Fudan University Shanghai Cancer Center, molecular classifications of TNBC and HR+/HER2− breast cancer were further developed.130–132\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Belows are highlighted some key factors contributing to the progression of breast cancer (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Based on these principles, numerous innovative explorations are emerging in both the surgical and radiotherapy fields (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The paradigm of systemic therapy has shifted from traditional methods to subtype-specific and personalized approaches (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This comprehensive review provides a synthesis of the latest current knowledge, focusing on recent breakthroughs and emerging trends in the pathogenesis, progression, diagnostics, treatment, and follow-up management of breast cancer (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Specific genes related to the progression of breast cancer\n\n\nGenes\nVariation\nCellular function and mechanisms of progression\nReference\n\n\n\nNF1\nMutation\nInhibiting RAS/Raf pathway and promote ER phosphorylation\n28\n\n\nESR1\nMutation, copy number variation, gene fusion\nInducing constitutive ER activity, leading to induction of ER target gene transcription that is resistant to endocrine blockade\n29–34\n\n\nALDH2\nCopy number gain\nCopy number gain of ALDH2 are associated with the expansion of subclones with high metastatic potential and shorter patient survival\n35,36\n\n\nGATA3\nMutation\nNegatively regulating the expression of several genes that promote breast cancer metastasis\n37\n\n\nKMT2C\nMutation\nDriving metastasis of TNBC via KDM6A-matrix metalloproteinase 3 axis\n38,39\n\n\nPTEN\nGene loss\nUp regulating CCL2 expression increase the number of CCR2-dependent macrophages, and promote PI3K/ Akt signaling pathway\n40\n\n\nFOXM1\nUpregulate gene expression\nPromoting the transcription of G2 and M phase genes in tumor cells through the PI3K/ Akt/mTOR pathway\n41\n\n\nYTHDF3\nUpregulate gene expression\nBinding to the m6A methylation site of YTHDF3\n42\n\n\nP53\nDownregulate gene expression\nPromoting the secretion of IL-1β by macrophages and the Wnt/β-catenin pathway\n43\n\n\nPI3KCA\nMutation\nActivating the PI3K enzyme and signaling pathway\n44,45\n\n\nRB1\nMutation\nAffecting the CDK-Rb-E2F signaling pathway\n44,46\n\n\n\nOpen in a new tab\nER estrogen receptor, TNBC triple-negative breast cancer, ALDH2 aldehyde dehydrogenase 2 family member 2, KDM6A lysine specific demethylase 6A, YTHDF3 YTH domain family 3, CCL2 C-C Motif Chemokine Ligand 2, PI3K phosphoinositide 3-kinase, RB Retinoblastoma retinoblastoma gene 1, CDK cyclin-dependent kinase, E2F E2 factorThe leading risk factors involve a combination of genetic predisposition, hormonal factors, reproductive history, and lifestyle choices (Fig. 2).5\nFig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is worth noting that retesting of the hormone and HER2 receptors should be considered in certain situations to optimize adjuvant systemic therapy.123Molecular subtypes of breast cancer\nThe past few decades have witnessed the promotion and popularization of the concept of classification-based treatment (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Lehmann et al. divided TNBC into six subtypes from the molecular classification: basal-like 1/2, immune modulative, mesenchymal, mesenchymal stem cell-like, and luminal androgen receptor subtypes,128and subsequently Burstein et al. refined the six TNBC subtypes into four subgroups.129 Based on the cohort from Fudan University Shanghai Cancer Center, molecular classifications of TNBC and HR+/HER2− breast cancer were further developed.130–132\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Belows are highlighted some key factors contributing to the progression of breast cancer (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Based on these principles, numerous innovative explorations are emerging in both the surgical and radiotherapy fields (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The paradigm of systemic therapy has shifted from traditional methods to subtype-specific and personalized approaches (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This comprehensive review provides a synthesis of the latest current knowledge, focusing on recent breakthroughs and emerging trends in the pathogenesis, progression, diagnostics, treatment, and follow-up management of breast cancer (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Specific genes related to the progression of breast cancer\n\n\nGenes\nVariation\nCellular function and mechanisms of progression\nReference\n\n\n\nNF1\nMutation\nInhibiting RAS/Raf pathway and promote ER phosphorylation\n28\n\n\nESR1\nMutation, copy number variation, gene fusion\nInducing constitutive ER activity, leading to induction of ER target gene transcription that is resistant to endocrine blockade\n29–34\n\n\nALDH2\nCopy number gain\nCopy number gain of ALDH2 are associated with the expansion of subclones with high metastatic potential and shorter patient survival\n35,36\n\n\nGATA3\nMutation\nNegatively regulating the expression of several genes that promote breast cancer metastasis\n37\n\n\nKMT2C\nMutation\nDriving metastasis of TNBC via KDM6A-matrix metalloproteinase 3 axis\n38,39\n\n\nPTEN\nGene loss\nUp regulating CCL2 expression increase the number of CCR2-dependent macrophages, and promote PI3K/ Akt signaling pathway\n40\n\n\nFOXM1\nUpregulate gene expression\nPromoting the transcription of G2 and M phase genes in tumor cells through the PI3K/ Akt/mTOR pathway\n41\n\n\nYTHDF3\nUpregulate gene expression\nBinding to the m6A methylation site of YTHDF3\n42\n\n\nP53\nDownregulate gene expression\nPromoting the secretion of IL-1β by macrophages and the Wnt/β-catenin pathway\n43\n\n\nPI3KCA\nMutation\nActivating the PI3K enzyme and signaling pathway\n44,45\n\n\nRB1\nMutation\nAffecting the CDK-Rb-E2F signaling pathway\n44,46\n\n\n\nOpen in a new tab\nER estrogen receptor, TNBC triple-negative breast cancer, ALDH2 aldehyde dehydrogenase 2 family member 2, KDM6A lysine specific demethylase 6A, YTHDF3 YTH domain family 3, CCL2 C-C Motif Chemokine Ligand 2, PI3K phosphoinositide 3-kinase, RB Retinoblastoma retinoblastoma gene 1, CDK cyclin-dependent kinase, E2F E2 factorThe leading risk factors involve a combination of genetic predisposition, hormonal factors, reproductive history, and lifestyle choices (Fig. 2).5\nFig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is worth noting that retesting of the hormone and HER2 receptors should be considered in certain situations to optimize adjuvant systemic therapy.123Molecular subtypes of breast cancer\nThe past few decades have witnessed the promotion and popularization of the concept of classification-based treatment (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Lehmann et al. divided TNBC into six subtypes from the molecular classification: basal-like 1/2, immune modulative, mesenchymal, mesenchymal stem cell-like, and luminal androgen receptor subtypes,128and subsequently Burstein et al. refined the six TNBC subtypes into four subgroups.129 Based on the cohort from Fudan University Shanghai Cancer Center, molecular classifications of TNBC and HR+/HER2− breast cancer were further developed.130–132\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Belows are highlighted some key factors contributing to the progression of breast cancer (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Based on these principles, numerous innovative explorations are emerging in both the surgical and radiotherapy fields (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The paradigm of systemic therapy has shifted from traditional methods to subtype-specific and personalized approaches (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This comprehensive review provides a synthesis of the latest current knowledge, focusing on recent breakthroughs and emerging trends in the pathogenesis, progression, diagnostics, treatment, and follow-up management of breast cancer (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Specific genes related to the progression of breast cancer\n\n\nGenes\nVariation\nCellular function and mechanisms of progression\nReference\n\n\n\nNF1\nMutation\nInhibiting RAS/Raf pathway and promote ER phosphorylation\n28\n\n\nESR1\nMutation, copy number variation, gene fusion\nInducing constitutive ER activity, leading to induction of ER target gene transcription that is resistant to endocrine blockade\n29–34\n\n\nALDH2\nCopy number gain\nCopy number gain of ALDH2 are associated with the expansion of subclones with high metastatic potential and shorter patient survival\n35,36\n\n\nGATA3\nMutation\nNegatively regulating the expression of several genes that promote breast cancer metastasis\n37\n\n\nKMT2C\nMutation\nDriving metastasis of TNBC via KDM6A-matrix metalloproteinase 3 axis\n38,39\n\n\nPTEN\nGene loss\nUp regulating CCL2 expression increase the number of CCR2-dependent macrophages, and promote PI3K/ Akt signaling pathway\n40\n\n\nFOXM1\nUpregulate gene expression\nPromoting the transcription of G2 and M phase genes in tumor cells through the PI3K/ Akt/mTOR pathway\n41\n\n\nYTHDF3\nUpregulate gene expression\nBinding to the m6A methylation site of YTHDF3\n42\n\n\nP53\nDownregulate gene expression\nPromoting the secretion of IL-1β by macrophages and the Wnt/β-catenin pathway\n43\n\n\nPI3KCA\nMutation\nActivating the PI3K enzyme and signaling pathway\n44,45\n\n\nRB1\nMutation\nAffecting the CDK-Rb-E2F signaling pathway\n44,46\n\n\n\nOpen in a new tab\nER estrogen receptor, TNBC triple-negative breast cancer, ALDH2 aldehyde dehydrogenase 2 family member 2, KDM6A lysine specific demethylase 6A, YTHDF3 YTH domain family 3, CCL2 C-C Motif Chemokine Ligand 2, PI3K phosphoinositide 3-kinase, RB Retinoblastoma retinoblastoma gene 1, CDK cyclin-dependent kinase, E2F E2 factorThe leading risk factors involve a combination of genetic predisposition, hormonal factors, reproductive history, and lifestyle choices (Fig. 2).5\nFig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is worth noting that retesting of the hormone and HER2 receptors should be considered in certain situations to optimize adjuvant systemic therapy.123Molecular subtypes of breast cancer\nThe past few decades have witnessed the promotion and popularization of the concept of classification-based treatment (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Lehmann et al. divided TNBC into six subtypes from the molecular classification: basal-like 1/2, immune modulative, mesenchymal, mesenchymal stem cell-like, and luminal androgen receptor subtypes,128and subsequently Burstein et al. refined the six TNBC subtypes into four subgroups.129 Based on the cohort from Fudan University Shanghai Cancer Center, molecular classifications of TNBC and HR+/HER2− breast cancer were further developed.130–132\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Belows are highlighted some key factors contributing to the progression of breast cancer (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Based on these principles, numerous innovative explorations are emerging in both the surgical and radiotherapy fields (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The paradigm of systemic therapy has shifted from traditional methods to subtype-specific and personalized approaches (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This comprehensive review provides a synthesis of the latest current knowledge, focusing on recent breakthroughs and emerging trends in the pathogenesis, progression, diagnostics, treatment, and follow-up management of breast cancer (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Specific genes related to the progression of breast cancer\n\n\nGenes\nVariation\nCellular function and mechanisms of progression\nReference\n\n\n\nNF1\nMutation\nInhibiting RAS/Raf pathway and promote ER phosphorylation\n28\n\n\nESR1\nMutation, copy number variation, gene fusion\nInducing constitutive ER activity, leading to induction of ER target gene transcription that is resistant to endocrine blockade\n29–34\n\n\nALDH2\nCopy number gain\nCopy number gain of ALDH2 are associated with the expansion of subclones with high metastatic potential and shorter patient survival\n35,36\n\n\nGATA3\nMutation\nNegatively regulating the expression of several genes that promote breast cancer metastasis\n37\n\n\nKMT2C\nMutation\nDriving metastasis of TNBC via KDM6A-matrix metalloproteinase 3 axis\n38,39\n\n\nPTEN\nGene loss\nUp regulating CCL2 expression increase the number of CCR2-dependent macrophages, and promote PI3K/ Akt signaling pathway\n40\n\n\nFOXM1\nUpregulate gene expression\nPromoting the transcription of G2 and M phase genes in tumor cells through the PI3K/ Akt/mTOR pathway\n41\n\n\nYTHDF3\nUpregulate gene expression\nBinding to the m6A methylation site of YTHDF3\n42\n\n\nP53\nDownregulate gene expression\nPromoting the secretion of IL-1β by macrophages and the Wnt/β-catenin pathway\n43\n\n\nPI3KCA\nMutation\nActivating the PI3K enzyme and signaling pathway\n44,45\n\n\nRB1\nMutation\nAffecting the CDK-Rb-E2F signaling pathway\n44,46\n\n\n\nOpen in a new tab\nER estrogen receptor, TNBC triple-negative breast cancer, ALDH2 aldehyde dehydrogenase 2 family member 2, KDM6A lysine specific demethylase 6A, YTHDF3 YTH domain family 3, CCL2 C-C Motif Chemokine Ligand 2, PI3K phosphoinositide 3-kinase, RB Retinoblastoma retinoblastoma gene 1, CDK cyclin-dependent kinase, E2F E2 factorThe leading risk factors involve a combination of genetic predisposition, hormonal factors, reproductive history, and lifestyle choices (Fig. 2).5\nFig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is worth noting that retesting of the hormone and HER2 receptors should be considered in certain situations to optimize adjuvant systemic therapy.123Molecular subtypes of breast cancer\nThe past few decades have witnessed the promotion and popularization of the concept of classification-based treatment (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Lehmann et al. divided TNBC into six subtypes from the molecular classification: basal-like 1/2, immune modulative, mesenchymal, mesenchymal stem cell-like, and luminal androgen receptor subtypes,128and subsequently Burstein et al. refined the six TNBC subtypes into four subgroups.129 Based on the cohort from Fudan University Shanghai Cancer Center, molecular classifications of TNBC and HR+/HER2− breast cancer were further developed.130–132\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Belows are highlighted some key factors contributing to the progression of breast cancer (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Based on these principles, numerous innovative explorations are emerging in both the surgical and radiotherapy fields (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The paradigm of systemic therapy has shifted from traditional methods to subtype-specific and personalized approaches (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This comprehensive review provides a synthesis of the latest current knowledge, focusing on recent breakthroughs and emerging trends in the pathogenesis, progression, diagnostics, treatment, and follow-up management of breast cancer (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Specific genes related to the progression of breast cancer\n\n\nGenes\nVariation\nCellular function and mechanisms of progression\nReference\n\n\n\nNF1\nMutation\nInhibiting RAS/Raf pathway and promote ER phosphorylation\n28\n\n\nESR1\nMutation, copy number variation, gene fusion\nInducing constitutive ER activity, leading to induction of ER target gene transcription that is resistant to endocrine blockade\n29–34\n\n\nALDH2\nCopy number gain\nCopy number gain of ALDH2 are associated with the expansion of subclones with high metastatic potential and shorter patient survival\n35,36\n\n\nGATA3\nMutation\nNegatively regulating the expression of several genes that promote breast cancer metastasis\n37\n\n\nKMT2C\nMutation\nDriving metastasis of TNBC via KDM6A-matrix metalloproteinase 3 axis\n38,39\n\n\nPTEN\nGene loss\nUp regulating CCL2 expression increase the number of CCR2-dependent macrophages, and promote PI3K/ Akt signaling pathway\n40\n\n\nFOXM1\nUpregulate gene expression\nPromoting the transcription of G2 and M phase genes in tumor cells through the PI3K/ Akt/mTOR pathway\n41\n\n\nYTHDF3\nUpregulate gene expression\nBinding to the m6A methylation site of YTHDF3\n42\n\n\nP53\nDownregulate gene expression\nPromoting the secretion of IL-1β by macrophages and the Wnt/β-catenin pathway\n43\n\n\nPI3KCA\nMutation\nActivating the PI3K enzyme and signaling pathway\n44,45\n\n\nRB1\nMutation\nAffecting the CDK-Rb-E2F signaling pathway\n44,46\n\n\n\nOpen in a new tab\nER estrogen receptor, TNBC triple-negative breast cancer, ALDH2 aldehyde dehydrogenase 2 family member 2, KDM6A lysine specific demethylase 6A, YTHDF3 YTH domain family 3, CCL2 C-C Motif Chemokine Ligand 2, PI3K phosphoinositide 3-kinase, RB Retinoblastoma retinoblastoma gene 1, CDK cyclin-dependent kinase, E2F E2 factorThe leading risk factors involve a combination of genetic predisposition, hormonal factors, reproductive history, and lifestyle choices (Fig. 2).5\nFig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is worth noting that retesting of the hormone and HER2 receptors should be considered in certain situations to optimize adjuvant systemic therapy.123Molecular subtypes of breast cancer\nThe past few decades have witnessed the promotion and popularization of the concept of classification-based treatment (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Lehmann et al. divided TNBC into six subtypes from the molecular classification: basal-like 1/2, immune modulative, mesenchymal, mesenchymal stem cell-like, and luminal androgen receptor subtypes,128and subsequently Burstein et al. refined the six TNBC subtypes into four subgroups.129 Based on the cohort from Fudan University Shanghai Cancer Center, molecular classifications of TNBC and HR+/HER2− breast cancer were further developed.130–132\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Belows are highlighted some key factors contributing to the progression of breast cancer (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Based on these principles, numerous innovative explorations are emerging in both the surgical and radiotherapy fields (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The paradigm of systemic therapy has shifted from traditional methods to subtype-specific and personalized approaches (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This comprehensive review provides a synthesis of the latest current knowledge, focusing on recent breakthroughs and emerging trends in the pathogenesis, progression, diagnostics, treatment, and follow-up management of breast cancer (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Specific genes related to the progression of breast cancer\n\n\nGenes\nVariation\nCellular function and mechanisms of progression\nReference\n\n\n\nNF1\nMutation\nInhibiting RAS/Raf pathway and promote ER phosphorylation\n28\n\n\nESR1\nMutation, copy number variation, gene fusion\nInducing constitutive ER activity, leading to induction of ER target gene transcription that is resistant to endocrine blockade\n29–34\n\n\nALDH2\nCopy number gain\nCopy number gain of ALDH2 are associated with the expansion of subclones with high metastatic potential and shorter patient survival\n35,36\n\n\nGATA3\nMutation\nNegatively regulating the expression of several genes that promote breast cancer metastasis\n37\n\n\nKMT2C\nMutation\nDriving metastasis of TNBC via KDM6A-matrix metalloproteinase 3 axis\n38,39\n\n\nPTEN\nGene loss\nUp regulating CCL2 expression increase the number of CCR2-dependent macrophages, and promote PI3K/ Akt signaling pathway\n40\n\n\nFOXM1\nUpregulate gene expression\nPromoting the transcription of G2 and M phase genes in tumor cells through the PI3K/ Akt/mTOR pathway\n41\n\n\nYTHDF3\nUpregulate gene expression\nBinding to the m6A methylation site of YTHDF3\n42\n\n\nP53\nDownregulate gene expression\nPromoting the secretion of IL-1β by macrophages and the Wnt/β-catenin pathway\n43\n\n\nPI3KCA\nMutation\nActivating the PI3K enzyme and signaling pathway\n44,45\n\n\nRB1\nMutation\nAffecting the CDK-Rb-E2F signaling pathway\n44,46\n\n\n\nOpen in a new tab\nER estrogen receptor, TNBC triple-negative breast cancer, ALDH2 aldehyde dehydrogenase 2 family member 2, KDM6A lysine specific demethylase 6A, YTHDF3 YTH domain family 3, CCL2 C-C Motif Chemokine Ligand 2, PI3K phosphoinositide 3-kinase, RB Retinoblastoma retinoblastoma gene 1, CDK cyclin-dependent kinase, E2F E2 factorThe leading risk factors involve a combination of genetic predisposition, hormonal factors, reproductive history, and lifestyle choices (Fig. 2).5\nFig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is worth noting that retesting of the hormone and HER2 receptors should be considered in certain situations to optimize adjuvant systemic therapy.123Molecular subtypes of breast cancer\nThe past few decades have witnessed the promotion and popularization of the concept of classification-based treatment (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Lehmann et al. divided TNBC into six subtypes from the molecular classification: basal-like 1/2, immune modulative, mesenchymal, mesenchymal stem cell-like, and luminal androgen receptor subtypes,128and subsequently Burstein et al. refined the six TNBC subtypes into four subgroups.129 Based on the cohort from Fudan University Shanghai Cancer Center, molecular classifications of TNBC and HR+/HER2− breast cancer were further developed.130–132\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Belows are highlighted some key factors contributing to the progression of breast cancer (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Based on these principles, numerous innovative explorations are emerging in both the surgical and radiotherapy fields (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The paradigm of systemic therapy has shifted from traditional methods to subtype-specific and personalized approaches (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This comprehensive review provides a synthesis of the latest current knowledge, focusing on recent breakthroughs and emerging trends in the pathogenesis, progression, diagnostics, treatment, and follow-up management of breast cancer (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This comprehensive review provides a synthesis of the latest current knowledge, focusing on recent breakthroughs and emerging trends in the pathogenesis, progression, diagnostics, treatment, and follow-up management of breast cancer (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Specific genes related to the progression of breast cancer\n\n\nGenes\nVariation\nCellular function and mechanisms of progression\nReference\n\n\n\nNF1\nMutation\nInhibiting RAS/Raf pathway and promote ER phosphorylation\n28\n\n\nESR1\nMutation, copy number variation, gene fusion\nInducing constitutive ER activity, leading to induction of ER target gene transcription that is resistant to endocrine blockade\n29–34\n\n\nALDH2\nCopy number gain\nCopy number gain of ALDH2 are associated with the expansion of subclones with high metastatic potential and shorter patient survival\n35,36\n\n\nGATA3\nMutation\nNegatively regulating the expression of several genes that promote breast cancer metastasis\n37\n\n\nKMT2C\nMutation\nDriving metastasis of TNBC via KDM6A-matrix metalloproteinase 3 axis\n38,39\n\n\nPTEN\nGene loss\nUp regulating CCL2 expression increase the number of CCR2-dependent macrophages, and promote PI3K/ Akt signaling pathway\n40\n\n\nFOXM1\nUpregulate gene expression\nPromoting the transcription of G2 and M phase genes in tumor cells through the PI3K/ Akt/mTOR pathway\n41\n\n\nYTHDF3\nUpregulate gene expression\nBinding to the m6A methylation site of YTHDF3\n42\n\n\nP53\nDownregulate gene expression\nPromoting the secretion of IL-1β by macrophages and the Wnt/β-catenin pathway\n43\n\n\nPI3KCA\nMutation\nActivating the PI3K enzyme and signaling pathway\n44,45\n\n\nRB1\nMutation\nAffecting the CDK-Rb-E2F signaling pathway\n44,46\n\n\n\nOpen in a new tab\nER estrogen receptor, TNBC triple-negative breast cancer, ALDH2 aldehyde dehydrogenase 2 family member 2, KDM6A lysine specific demethylase 6A, YTHDF3 YTH domain family 3, CCL2 C-C Motif Chemokine Ligand 2, PI3K phosphoinositide 3-kinase, RB Retinoblastoma retinoblastoma gene 1, CDK cyclin-dependent kinase, E2F E2 factorThe leading risk factors involve a combination of genetic predisposition, hormonal factors, reproductive history, and lifestyle choices (Fig. 2).5\nFig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Specific genes related to the progression of breast cancer\n\n\nGenes\nVariation\nCellular function and mechanisms of progression\nReference\n\n\n\nNF1\nMutation\nInhibiting RAS/Raf pathway and promote ER phosphorylation\n28\n\n\nESR1\nMutation, copy number variation, gene fusion\nInducing constitutive ER activity, leading to induction of ER target gene transcription that is resistant to endocrine blockade\n29–34\n\n\nALDH2\nCopy number gain\nCopy number gain of ALDH2 are associated with the expansion of subclones with high metastatic potential and shorter patient survival\n35,36\n\n\nGATA3\nMutation\nNegatively regulating the expression of several genes that promote breast cancer metastasis\n37\n\n\nKMT2C\nMutation\nDriving metastasis of TNBC via KDM6A-matrix metalloproteinase 3 axis\n38,39\n\n\nPTEN\nGene loss\nUp regulating CCL2 expression increase the number of CCR2-dependent macrophages, and promote PI3K/ Akt signaling pathway\n40\n\n\nFOXM1\nUpregulate gene expression\nPromoting the transcription of G2 and M phase genes in tumor cells through the PI3K/ Akt/mTOR pathway\n41\n\n\nYTHDF3\nUpregulate gene expression\nBinding to the m6A methylation site of YTHDF3\n42\n\n\nP53\nDownregulate gene expression\nPromoting the secretion of IL-1β by macrophages and the Wnt/β-catenin pathway\n43\n\n\nPI3KCA\nMutation\nActivating the PI3K enzyme and signaling pathway\n44,45\n\n\nRB1\nMutation\nAffecting the CDK-Rb-E2F signaling pathway\n44,46\n\n\n\nOpen in a new tab\nER estrogen receptor, TNBC triple-negative breast cancer, ALDH2 aldehyde dehydrogenase 2 family member 2, KDM6A lysine specific demethylase 6A, YTHDF3 YTH domain family 3, CCL2 C-C Motif Chemokine Ligand 2, PI3K phosphoinositide 3-kinase, RB Retinoblastoma retinoblastoma gene 1, CDK cyclin-dependent kinase, E2F E2 factorThe leading risk factors involve a combination of genetic predisposition, hormonal factors, reproductive history, and lifestyle choices (Fig. 2).5\nFig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The leading risk factors involve a combination of genetic predisposition, hormonal factors, reproductive history, and lifestyle choices (Fig. 2).5.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is worth noting that retesting of the hormone and HER2 receptors should be considered in certain situations to optimize adjuvant systemic therapy.123Molecular subtypes of breast cancer\nThe past few decades have witnessed the promotion and popularization of the concept of classification-based treatment (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Lehmann et al. divided TNBC into six subtypes from the molecular classification: basal-like 1/2, immune modulative, mesenchymal, mesenchymal stem cell-like, and luminal androgen receptor subtypes,128and subsequently Burstein et al. refined the six TNBC subtypes into four subgroups.129 Based on the cohort from Fudan University Shanghai Cancer Center, molecular classifications of TNBC and HR+/HER2− breast cancer were further developed.130–132\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "It is worth noting that retesting of the hormone and HER2 receptors should be considered in certain situations to optimize adjuvant systemic therapy.123Molecular subtypes of breast cancer\nThe past few decades have witnessed the promotion and popularization of the concept of classification-based treatment (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Lehmann et al. divided TNBC into six subtypes from the molecular classification: basal-like 1/2, immune modulative, mesenchymal, mesenchymal stem cell-like, and luminal androgen receptor subtypes,128and subsequently Burstein et al. refined the six TNBC subtypes into four subgroups.129 Based on the cohort from Fudan University Shanghai Cancer Center, molecular classifications of TNBC and HR+/HER2− breast cancer were further developed.130–132\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Molecular subtypes of breast cancer\nThe past few decades have witnessed the promotion and popularization of the concept of classification-based treatment (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Lehmann et al. divided TNBC into six subtypes from the molecular classification: basal-like 1/2, immune modulative, mesenchymal, mesenchymal stem cell-like, and luminal androgen receptor subtypes,128and subsequently Burstein et al. refined the six TNBC subtypes into four subgroups.129 Based on the cohort from Fudan University Shanghai Cancer Center, molecular classifications of TNBC and HR+/HER2− breast cancer were further developed.130–132\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The past few decades have witnessed the promotion and popularization of the concept of classification-based treatment (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Belows are highlighted some key factors contributing to the progression of breast cancer (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Belows are highlighted some key factors contributing to the progression of breast cancer (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Based on these principles, numerous innovative explorations are emerging in both the surgical and radiotherapy fields (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The paradigm of systemic therapy has shifted from traditional methods to subtype-specific and personalized approaches (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Based on these principles, numerous innovative explorations are emerging in both the surgical and radiotherapy fields (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Based on these principles, numerous innovative explorations are emerging in both the surgical and radiotherapy fields (Fig. 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The paradigm of systemic therapy has shifted from traditional methods to subtype-specific and personalized approaches (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The paradigm of systemic therapy has shifted from traditional methods to subtype-specific and personalized approaches (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The paradigm of systemic therapy has shifted from traditional methods to subtype-specific and personalized approaches (Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  }
]